Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) Overview | 8 | 1 |
| Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) Comparative Analysis | 9 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Therapeutics under Development by Companies | 10 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Products under Development by Companies | 14 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Products under Investigation by Universities/Institutes | 15 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Companies Involved in Therapeutics Development | 16 | 6 |
| Acucela Inc. | 16 | 1 |
| Alkeus Pharmaceuticals, Inc. | 17 | 1 |
| Astellas Pharma Inc. | 18 | 1 |
| Copernicus Therapeutics, Inc. | 19 | 1 |
| Iris Pharma | 20 | 1 |
| Sanofi | 21 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 25 |
| ALK-001 Drug Profile | 31 | 1 |
| echothiophate iodide Drug Profile | 32 | 1 |
| emixustat hydrochloride Drug Profile | 33 | 4 |
| Gene Therapy 1 to Activate ABCA4 for Stargardt Disease Drug Profile | 37 | 1 |
| Gene Therapy to Activate ABCA4 for Stargardt Disease Drug Profile | 38 | 1 |
| MA09-hRPE Drug Profile | 39 | 10 |
| Oligonucleotides to Activate ABCA4 for Stargardt Disease Drug Profile | 49 | 1 |
| ramiprilat Drug Profile | 50 | 1 |
| SAR-422459 Drug Profile | 51 | 2 |
| soraprazan Drug Profile | 53 | 1 |
| Stem Cell Therapy for Ophthalmic Disorders Drug Profile | 54 | 1 |
| VM-200 Drug Profile | 55 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Dormant Projects | 56 | 1 |
| Juvenile Macular Degeneration (Stargardt Disease) Product Development Milestones | 57 | 10 |
| Featured News &Press Releases | 57 | 1 |
| May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases | 57 | 1 |
| May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease | 57 | 1 |
| Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies | 58 | 1 |
| Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration | 58 | 1 |
| Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt s Macular Degeneration Phase 1 Trial in the United Kingdom | 59 | 1 |
| Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials | 60 | 1 |
| May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells | 61 | 1 |
| Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration | 61 | 1 |
| Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt s Macular Dystrophy | 61 | 1 |
| Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy | 62 | 1 |
| Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells | 63 | 1 |
| Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone | 64 | 1 |
| Dec 17, 2012: ACT Completes Higher-Dosage Cohort In European Clinical Trial For Stargardt's Macular Dystrophy Using Retinal Pigment Epithelial Cells | 64 | 1 |
| Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells | 65 | 1 |
| Nov 08, 2012: Advanced Cell Technology Announces Interim Data From Three Ongoing Macular Degeneration Trials | 65 | 2 |
| Appendix | 67 | 2 |
| Methodology | 67 | 1 |
| Coverage | 67 | 1 |
| Secondary Research | 67 | 1 |
| Primary Research | 67 | 1 |
| Expert Panel Validation | 67 | 1 |
| Contact Us | 67 | 1 |
| Disclaimer | 68 | 1 |